Alterity Therapeutics Limited (ASX:ATH) disclosed that shareholders passed all 11 resolutions put to a vote at the company's Annual General Meeting held on 20 November 2026, with results determined by poll across all resolutions.
Key Points
- All 11 resolutions were carried by poll at the AGM held on 20 November 2026.
- Directors Peter Marks and Lawrence Gozlan were re-elected, receiving 81.38% and 82.81% of poll votes in favour respectively.
- The 7.1A placement mandate was approved with 87.58% of poll votes in favour.
- Options were approved for directors Peter Marks, Lawrence Gozlan, Julian Babarczy, Ann Cunningham, and CEO David Stamler, as well as approval of potential termination benefits for David Stamler.
- The confirmation of the auditor's appointment passed with 97.73% of poll votes in favour.
Director Re-Elections and Remuneration Report
The re-election of Peter Marks as a director was carried with 81.38% of poll votes in favour and 18.62% against. The re-election of Lawrence Gozlan was carried with 82.81% in favour and 17.19% against. The adoption of the Remuneration Report was also put to a poll, receiving 79.34% of votes in favour and 20.66% against. The meeting was held on 20 November 2026, in accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001.
Options Approved for Directors and CEO
Shareholders approved the issuance of options to five individuals. Approval to issue options to Peter Marks was carried with 75.17% in favour and 24.83% against. Options for Lawrence Gozlan were approved with 75.25% in favour, and options for Julian Babarczy were approved with 75.23% in favour. Options for Ann Cunningham were approved with 80.62% in favour and 19.38% against. The resolution to issue options to CEO David Stamler was carried with 78.29% in favour and 21.71% against, all decided by poll.
Placement Mandate, Termination Benefits, and Auditor Confirmation
The approval of a 7.1A placement mandate was carried with 87.58% of poll votes in favour and 12.42% against. The resolution approving potential termination benefits for CEO David Stamler was carried with 78.97% in favour and 21.03% against. The confirmation of the appointment of the company's auditor received the highest level of support among all resolutions, passing with 97.73% of poll votes in favour and 2.27% against. The company is a clinical stage biotechnology company based in Melbourne, Australia, and San Francisco, California, USA.




Please wait processing your request...